Since approved and emerging cancer immunotherapeutics include immune checkpoint inhibitors, we have assessed the effect of anti-PD-1 treatment on HSP90 expression in refractory/relapsed lymphoma patients. This evidence concerns the gene HSP90AB1 and lymphoma.